In the Italian real-world study ELECTRA-i, carried out on 115 patients with RA, after 12 months of treatment with filgotinib and baricitinib the blood counts of NK CD56+ counts increased in a statistically significant fashion, since these drugs are not able to bind JAK3 (Figure 3). Here, JAK3 is linked to rheumatoid arthritis.